First-generation psychedelics have two business problems that are hard to fix: their effect lasts for hours, so someone has to supervise the patient in a clinic (expensive), and the original compounds are natural substances you can't patent tightly (weak IP). This is the story of a group of chemists trying to design new molecules to solve both — making the effect shorter to cut clinic time, or, at the far end, cutting the trip out entirely while keeping the brain-rewiring benefit, so you can take it like an ordinary pill. And it's a very early, very uncertain bet, because the biggest question still has no answer: can you actually separate the "trip" from the "benefit"?
Berenberg upgrades Eli Lilly to buy, lifts target to $1,400
Berenberg analyst Kerry Holford upgraded Eli Lilly to buy and raised her price target to $1,400, implying almost 25% upside, backing the drugmaker to extend its lead in the fast-growing obesity market. Holford said the firm's latest return-on-R&D-investment analysis confirms Lilly's track record of best-in-class returns and that she sees upside to its 2026 guidance. She argued the external pipeline investment fueled by Lilly's obesity success remains underestimated, noting the company has committed about $60 billion across more than 25 deals this year. Holford said Zepbound and Mounjaro are established leaders in obesity and diabetes, and expects the imminent diabetes approval of oral GLP-1 drug Foundayo to unlock significant demand, aided by the Medicare Bridge program. She also cited recent acquisitions that diversify the pipeline, including the roughly $4 billion purchase of AtaiBeckley, which adds psychedelic assets targeting mental health, and the $8 billion acquisition of Centessa, which takes Lilly into sleep-wake disorders such as narcolepsy. Holford said Lilly's premium valuation is justified: the stock trades at 23.4 times 2027 earnings versus a global peer average of 13.6 times, but she argued its superior growth, pipeline breadth and research productivity warrant a more significant premium.
Lobe Sciences to Present Low-Dose L-130 Clinical Data at Neuropsychiatric Summit
Lobe Sciences Ltd. announced that Chairman and Chief Executive Officer Dr. Frederick D. Sancilio will present clinical and preclinical data for Conjugated Psilocin, or L-130, at the 9th Neuropsychiatric Drug Development Summit, held September 15-17, 2026 in Boston, Massachusetts. Dr. Sancilio's presentation, titled "Reimagining Psychedelic Therapeutics for Daily Outpatient Use: Advancing Low-Dose Psilocin Beyond the Hallucinogenic Paradigm," is scheduled for 11:00 a.m. ET on Wednesday, September 16 in the summit's preclinical and translational track. The presentation sets out the case for patented L-130 as a candidate suited to daily outpatient dosing rather than the supervised in-clinic administration that psychedelic-class candidates typically require, covering the compound's formulation characteristics as a patented salt of psilocin, the active moiety itself rather than a prodrug, together with first-in-human results in ten subjects showing consistent oral pharmacokinetics and preclinical findings on daily low-dose administration. Lobe will also exhibit throughout the three-day summit, which brings together senior discovery, translational, clinical, regulatory and business development leaders from large pharmaceutical companies, biotechnology companies and investors active in neuropsychiatric drug development. L-130 is initially being developed for cluster headache, with co-development programs underway for PTSD, substance use disorder, generalized anxiety disorder and other neuropsychiatric disorders, while the company is also advancing S-100 for sickle cell disease, with Phase 3 clinical development anticipated to commence in mid-2027.
Lilly completes acquisition of AtaiBeckley to advance treatment-resistant depression therapies
Eli Lilly and Company has completed its acquisition of AtaiBeckley Inc., a clinical-stage biopharmaceutical company developing rapid-acting neuroplastogens for mental health conditions. AtaiBeckley's lead investigational program, BPL-003, targets treatment-resistant depression. The transaction was approved by AtaiBeckley shareholders at a special meeting held prior to closing. Carole Ho, Lilly executive vice president and president of Lilly Neuroscience, said AtaiBeckley's neuroplastogens have the potential to open a new paradigm of treatment with rapid-acting therapeutics designed to move away from chronic dosing. Lilly said it is committed to advancing the pipeline for patients who need more options.
AbbVie Raises Neuroscience Sales Guidance to $12.7 Billion for 2026
AbbVie now expects its neuroscience portfolio to generate approximately $12.7 billion in revenue during 2026, raising guidance by another $100 million after a strong first half of the year. The portfolio generated $10.8 billion last year and continues to grow at a double-digit pace. Second-quarter neuroscience revenue climbed 20.3% year over year to $3.23 billion, led by Vraylar at $1.07 billion, therapeutic Botox at $1.04 billion, and migraine drugs Ubrelvy and Qulipta at $742 million combined. AbbVie also acquired Gilgamesh Pharmaceuticals' lead drug candidate bretisilocin for $906 million upfront, with another $300 million tied to future development milestones, as part of its push into psychedelics-based medicines for major depressive disorder.
Eli Lilly to Acquire AtaiBeckley for $2.8 Billion Upfront
Eli Lilly has entered into a definitive agreement to acquire clinical-stage biotech AtaiBeckley for an initial upfront payment of $2.8 billion. Under the deal, Lilly will pay AtaiBeckley shareholders $6.75 per share in cash upon closing, with the potential for an additional $2.50 per share through contingent value rights if specified development and regulatory milestones for the BPL-003 and VLS-01 programs are achieved, which could increase the total deal value by up to $1.0 billion. The acquisition is driven by AtaiBeckley's pipeline of novel psychedelic therapies for mental health disorders, including lead asset BPL-003, an intranasal formulation of mebufotenin benzoate in Phase III for treatment-resistant depression that has received FDA Breakthrough Therapy designation. The transaction, expected to close in the third quarter of 2026, is part of Lilly's broader 2026 acquisition spree totaling more than $20 billion in biotech deals to diversify beyond GLP-1 therapies.
AtaiBeckley Trades at 13.2x Price-to-Book After Eli Lilly’s $3.8 Billion Bid
Eli Lilly and Company has agreed to acquire AtaiBeckley in a cash and contingent value rights deal valued at up to $3.8 billion, putting fresh focus on the stock's valuation. AtaiBeckley's share price surged 33.4% on the announcement and is up 84.75% year to date, with a one-year total shareholder return of 156.27% contrasting with a five-year total shareholder return that remains down 58.57%. The stock last closed at $7.15, above Eli Lilly's $6.75 per share cash offer, and its price-to-book multiple stands at 13.2x, more than five times the US pharmaceuticals industry average of 2.4x and more than double the peer group average of 5.5x. The company recorded a loss of $663.4 million on only $3.5 million of reported revenue and is forecast to remain unprofitable over the next three years, suggesting the market is pricing in substantial future potential for its mental health pipeline and clinical-stage assets.
Clearmind Medicine reports positive retention results for intranasal MEAI formulation
Clearmind Medicine announced positive ex vivo mucoadhesion results for its intranasal formulation of MEAI, a psychedelic-based neuroplastogen. The study showed that the new formulation, which uses a nasal drug-delivery system, consistently maintained a greater proportion of its initially adhered dose on rabbit nasal mucosa over a 30-minute period compared with a standard MEAI solution. These results highlight the contribution of the mucoadhesive polymer system and validate Clearmind's nasal drug-delivery platform, which is designed to increase formulation residence at mucosal surfaces. Extended residence time is a key factor in effective intranasal drug administration, potentially improving absorption and therapeutic efficiency for Alcohol Use Disorder and other indications. Clearmind is a clinical-stage biotechnology company pioneering non‑hallucinogenic neuroplastogen‑derived treatments.
Psychedelic stocks surge after Eli Lilly agrees to acquire AtaiBeckley
Shares of psychedelic drug developers are surging premarket after Eli Lilly announced a definitive agreement to acquire AtaiBeckley Inc., validating the sector. AtaiBeckley shares rose 30.8%, Compass Pathways gained 7.4%, and GH Research jumped 18.9%. Lilly will pay $6.75 per share in cash, plus up to $2.50 per share via a Contingent Value Right tied to milestones for lead programs BPL-003 and VLS-01, implying an upfront equity value of about $2.8 billion and additional potential value of roughly $1.0 billion. The deal is expected to close in the third quarter. RBC Capital said GH Research represents the most direct read-through given its lead asset GH001 is nearly identical to AtaiBeckley's BPL-003, both based on 5-MeO-DMT for treatment-resistant depression, and maintained an Outperform rating with a $40 price target.
AtaiBeckley Joins Russell 2000 and 3000 Indices, Canaccord Raises Price Target to $17
AtaiBeckley N.V. will be added to the Russell 2000 and Russell 3000 indices effective June 29, a move the company notes is significant given over $12 trillion in assets benchmarked to Russell indexes. Canaccord Genuity subsequently raised its price target on the stock from $15 to $17 on July 7, implying more than 227% upside, while reiterating a Buy rating. The revision followed completion of dosing in the Phase 2 Elumina trial of VLS-01 for treatment-resistant depression, with the company targeting Phase 3 development for major depressive disorder and potential expansion into generalized anxiety disorder. AtaiBeckley is a clinical-stage biopharmaceutical company focused on mental health therapies, with a pipeline that includes BPL-003 in Phase 2 for treatment-resistant depression and alcohol addiction, and RL-007 for cognitive decline from schizophrenia.
AtaiBeckley Completes Dosing in Phase 2b Trial of VLS-01 for Depression
AtaiBeckley Inc. has completed patient dosing in its Phase 2b Elumina clinical trial evaluating VLS-01, a DMT buccal film, for treatment-resistant depression. The multi-center, double-blind, placebo-controlled study enrolled 156 participants, with topline results expected in the fourth quarter of 2026. The company plans to advance VLS-01 into Phase 3 development for major depressive disorder, while generalized anxiety disorder remains a potential future indication. Canaccord raised its price target on ATAI to $17 from $15 and maintained a Buy rating, noting the trial remains on track.
Three Psychedelic Stocks With Potential Clinical Trial Catalysts
Optimi Health, AtaiBeckley, and COMPASS Pathways are three psychedelic medicine companies with upcoming clinical trial catalysts that could reshape their risk-reward profiles. Optimi Health, a Canadian manufacturer with a Health Canada-licensed GMP facility, is already shipping pharmaceutical-grade MDMA and psilocybin into Australia's reimbursed prescription market, though its revenue remains below CA$1 million. AtaiBeckley has multiple Phase 2 programs targeting treatment-resistant depression and social anxiety, with Phase IIb data expected in 2026 and potential progression to Phase 3 trials, but it faces widening losses and high funding risk. COMPASS Pathways is advancing its psilocybin therapy COMP360 in Phase III for treatment-resistant depression and plans to file a rolling NDA with the FDA, yet it remains pre-revenue with a history of shareholder dilution.
XTL Biopharmaceuticals completes acquisition of Psyga Bio, pivots to psychedelic medicine
XTL Biopharmaceuticals has completed its acquisition of Psyga Bio Ltd., acquiring approximately 83.40% of Psyga Bio's issued and outstanding share capital on a fully diluted basis. The deal transforms XTL into a dedicated psychedelic medicine company, with operations centered on an advanced clinical pipeline, a licensed GMP manufacturing facility, and a proprietary library of over 250 mushroom strains. The acquisition was funded through the issuance of American Depositary Shares representing roughly 33.36% of XTL's post-issuance capital, with Psyga shareholders eligible for up to an additional 25.02% of XTL's capital upon achieving three clinical and commercial milestones. Concurrently, a $1,500,000 private placement was wired to the company's treasury to support clinical and business plans. XTL highlighted a favorable U.S. regulatory environment following an April 2026 executive order by President Trump directing the FDA and DEA to accelerate psychedelic drug research and approvals.